Nuvectis Pharma's third quarter 2026 results feature a $140M cash balance and China drug approval

Nuvectis Pharma reported a third quarter 2026 net loss of $30.1 million, significantly widening from $7.5 million in the prior year due to $21.8 million in licensing and milestone payments. The company substantially strengthened its balance sheet, ending the quarter with $140.7 million in cash following a successful $115 million follow-on public offering.

Key Highlights

• Cash and equivalents increased to $140.7 million as of September 30, 2026, extending the company's projected operational runway into the second half of 2029.
• Lead candidate ciprocopan (NXP100) received its first global approval in China for PNH in July 2026, with an update on the U.S. regulatory path expected by year-end 2026.
• Clinical data for NXP200 presented at ESMO showed a 40.0% Objective Response Rate in high-grade glioma and a 42.9% ORR in low-grade glioma cohorts.
• Research and development expenses surged to $27.4 million, primarily driven by the $20 million upfront payment to Haisco Pharmaceutical for the in-licensing of NXP100 and NXP200.